Clinical Trials | January 01, 2026
SOFIE Biosciences doses first patient in Phase 3 trial of novel cancer imaging agent
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Theracor is derived from human umbilical cord extracellular matrix (ECM) and is designed to cover, protect, and maintain a moist wound environment
The accelerated review covers WCK 5222 for multiple critical infections
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments
Applications include detailed scientific rationale and supporting clinical evidence
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
Subscribe To Our Newsletter & Stay Updated
